Pancreatic cancer treatment after FOLFIRINOX: prognostic importance of chemotherapy dose intensity and albumin/globulin ratio in second line

Authors : Özgen Ahmet YILDIRIM, Erkan ERDUR

Pages : 156-160

Doi:10.32322/jhsm.1011658

View : 28 | Download : 13

Publication Date : 2022-01-17

Article Type : Research Paper

Abstract :Aim: Pancreatic adenocarcinoma insert ignore into journalissuearticles values(PA); is the seventh most common cause of cancer-related mortality. Our primary endpoint of study was to determine the relationship between albumin/globulin ratio insert ignore into journalissuearticles values(AGR); and progression-free and overall survival insert ignore into journalissuearticles values(PFS and OS); in second-line treatment after FOLFIRINOX. Our secondary endpoint was to assess treatment side effects and the relationship of treatment dose intensity with treatment type and AGR. Material and Method: PA patients who followed-up between January 2014 and January 2021 were evaluated retrospectively. Age, gender, ECOG score and AGR recorded at the beginning of the second-line treatment. Thrombocytopenia, neutropenia, chemotherapy type, chemotherapy dose intensity, PFS and OS were recorded during the second-line treatment. Results: Median age 64 insert ignore into journalissuearticles values(44-80);, 72 insert ignore into journalissuearticles values(70.6%); male, 102 metastatic PA patients were evaluated. 76 insert ignore into journalissuearticles values(74.5%); patients were ECOG 0-1, 26 insert ignore into journalissuearticles values(25.5%); patients were ECOG 2. Of these patients in the second step, 68 insert ignore into journalissuearticles values(66.7%); received single-agent gemcitabine and 34 insert ignore into journalissuearticles values(33.3%); received Nab-paclitaxel + gemcitabine treatment. Progression and exitus events occurred in all cases. Median PFS was 166.8 days in the AGR>1.2 group, it was 80.7 days in the AGR 1.2 group, it was 144 days in the AGR 1.2 group, it was 71.3% in the AGR<1.2 group insert ignore into journalissuearticles values(p=0.002);. Conclusion: Even with palliative and advanced treatment, achieving a dose density close to 80% is a good prognostic indicator. AGR is a prognostic marker that remains effective in advanced stages of PA.
Keywords : pancreatic cancer, dose intensity, albumin globulin ratio